Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTACT: Low-dose Colchicine vs Naproxen in Acute Gout
NCT01994226Phase 4
Key facts
- Status
- Completed
- Start
- Jan 2014
- Primary completion
- Mar 2016
- Countries
- 1
- Sponsor
- Keele University
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Drugs
- colchicine
- Conditions
- gout
01
Overview
Phase 4, randomised, open-label trial of colchicine in gout (2 arms), sponsored by Keele University. Primary endpoint: Change in worst pain intensity in the previous 24 hours. Started Jan 2014; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Low-dose colchicine
500 mcg every eight hours for four days
Naproxen
750 mg initial dose followed by 250 mg every eight hours for up to seven days
03
Who it enrols
Adults 18+ with acute gout attack. Excludes CKD stage 4/5, unstable medical conditions, recent GI bleed/ulcer, anticoagulant use, and pregnancy.
04
Endpoints
Primary
Change in worst pain intensity in the previous 24 hours
Secondary
Side effects
Time to treatment response
Patient global assessment of response to treatment
Adherence to treatment
Use of other medications for pain relief
Cost effectiveness
Beyond the preview
Go deeper on NCT01994226.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01994226.